- Company
- First-ever RET inhibitor 'Retevmo' attempts reimbursement
- by Eo, Yun-Ho Mar 31, 2022 05:58am
- The first RET-targeted anticancer therapy is attempting to receive insurance reimbursement in Korea. According to industry sources, Lilly Korea has recently submitted a reimbursement application for its ‘Retevmo (selpercatinib) that targets the RET (Rearranged during transfection)-gene fusions. After receiving approval from the Ministry
- Company
- Kidney care is also important for diabetic patients
- by Eo, Yun-Ho Mar 30, 2022 06:09am
- SGLT-2 inhibitors, which have obtained indications for chronic kidney disease, are emerging as the mainstay of chronic disease management along with diabetes. According to data from the Korean Diabetes Association, the rate of kidney disease accompanied by type 2 diabetes patients in Korea was about 30%, and one in three diabetes patients in
- Company
- Dupixent shows marked effect in Korean severe asthma patient
- by Mar 30, 2022 06:09am
- Study analysis results on Sanofi’s allergic disease treatment ‘Dupixent (dupilumab)’ have shown that the drug has a superior effect on severe asthma patients in Korea. Based on the sub-analysis results, Sanofi is pursuing a reimbursement extension for Dupixent in asthma in Korea. At the webinar on the ‘Present state of severe asthma treat
- Company
- Daewoong’s ‘Fexclu’ speeds up overseas market penetration
- by Kim, Jin-Gu Mar 29, 2022 05:54am
- Daewoong Pharmaceutical is working to target the global market with ‘Fexclu tab (fexuprazan),’ its new drug for P-CAB gastroesophageal reflux disease (GERD).’ The company had signed 6 export agreements with 15 countries in North America, Latin America, China, and the Middle East, which amounts to &8361;1.2 trillion. In the case of the So
- Company
- Wakix, a narcolepsy tx, can be prescribed at hospitals
- by Eo, Yun-Ho Mar 29, 2022 05:53am
- Wakix, a narcolepsy treatment, can be prescribed at general hospitals. According to related industries, Mitsubishi Tanabe Pharma's Wakix passed the Drug Committee of Seoul National University Hospital and other medical institutions. Wakix has been competing with Handok Teva's Nuvigil since last month as insurance benefits have been availab
- Company
- Expanding Entresto benefits/maximizing tx for inpatients
- by Mar 29, 2022 05:53am
- Entresto, Novartis' chronic heart failure treatment, has expanded both indications and benefits. Enresto can be used even in patients with more than 40% and less than 60% of the ejection fraction, which has been in great demand. In addition, it is expected that Entresto's position will be further strengthened as hospitalized heart failure patien
- Company
- Four types of PE exemption drugs listed in one month…
- by Eo, Yun-Ho Mar 28, 2022 06:10am
- Coverage expansions of new drugs continue to be reported. In fact, four new drugs were successfully listed last month. According to industry sources, starting with Astellas’ ‘Xospata (gilteritinib)’ in March, Novartis’s ‘Kymirah (tisagenlecleucel),’ Roche’s ‘Rozlytrek (entrectinib),’ Bayer’s ‘Vitrakvi (larotrectinib)’ were lis
- Company
- Sanofi Launches 3rd Generation Antihistamine Alllegra
- by Nho, Byung Chul Mar 28, 2022 06:10am
- Sanofi Korea announced on the 23rd that it released Allegra 120mg, an allergic rhinitis treatment with 3rd generation antihistamine ingredients, in February. Most 3rd generation antihistamines are Rx drugs, which can only be taken after prescription at clinics, but Allegra can be purchased without prescription at pharmacies with permission
- Company
- Antengene’s first new drug Xpovio lands in hospitals
- by Eo, Yun-Ho Mar 25, 2022 05:48am
- ‘Xpovio, the first drug introduced by the Chinese pharma company Antengene, has landed in general hospitals. According to industry sources, the company’s anticancer drug Xpovio (Selinexor) has passed the review of drug committees (DCs) at 4 of the Big 5 tertiary hospitals - Samsung Medical Center (SMC), Seoul National University H
- Company
- SK Biopharm targets US sales of Xcopri
- by Kim, Jin-Gu Mar 25, 2022 05:48am
- SK Biopharm announced that it will double U.S. sales of Cenobamate (Xcopri) this year. Cho Jung-woo, CEO of SK Biopharm, presented this year's goal at an online press conference on the 24th. SK Biopharm generated 78.2 billion won in sales from Cenobamate in the U.S. last year. Sales have more than increased seven times compared to 10.6 billio
